Letaplimab represents a unique clinical method for addressing complement-mediated diseases. This antibody targets C1q, a critical component of the complement system, effectively disrupt its first activation. Initial https://kaleqvhb965734.activoblog.com/51551882/letaplimab-a-innovative-therapeutic-strategy